Multiple Myeloma
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
It's Time to Use MRD for Clinical Decision Making: MRD as a Surrogate Marker for PFS/OS, for Maintenance Decision Making, Renal Allografting Patient Qualification, and Solitary Plasmacytomas Definition
FEATURING
Jeffrey Wolf
- 35 views
- November 18, 2019